key: cord-1028013-c861754a
authors: Su, Q.; Hu, J.-x.; Lin, H.-s.; Zhang, Z.; Zhu, E. C.; Zhang, C.-g.; Wang, D.-y.; Gao, Z.-h.; Cao, B.-w.
title: Prevalence and risks of severe events for cancer patients with COVID-19 infection: a systematic review and meta-analysis
date: 2020-06-24
journal: nan
DOI: 10.1101/2020.06.23.20136200
sha: 50bc1217735ee04f5f14acad21c69f797a703389
doc_id: 1028013
cord_uid: c861754a

Background The corona virus disease 2019 (COVID-19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases. In this meta-analysis, we studied the prevalence of cancer among patients with COVID-19 infection and their risks of severe events. Methods We searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics. We extracted data following PICO (patient, intervention, comparison and outcome) chart. Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data. We assessed the studies risk of bias in accordance to the adjusted Joanna Briggs Institute. We estimated the prevalence or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects. Findings Out of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19. The total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), higher than that of the total cancer rate (0.29%) in China. Stratification analysis showed that the overall cancer prevalence of COVID-19 patients in China was 2.59% (95% CI, 1.72% to 3.90%), and the prevalence reached 3.79% in Wuhan (95% CI, 2.51% to 5.70%) and 2.31% (95% CI, 1.16% to 4.57%) in other areas outside Wuhan in China. The incidence of ICU admission in cancer patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%), much higher than the overall rates of COVID-19 patients in China. The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes (OR 1.32; 95% CI, 0.42 to 4.11; p=0.19), hypertension (OR 1.27; 95% CI, 0.35 to 4.62; p=0.13), and respiratory diseases (OR 0.79; 95% CI, 0.47 to 1.33; p=0.45). Interpretation This comprehensive meta-analysis on the largest number of patients to date provides solid evidence that COVID-19 infection significantly and negatively affected the disease course and prognosis of cancer patients. Awareness of this could help guide clinicians and health policy makers in combating cancer in the context of COVID-19 pandemic.

The corona virus disease 2019 (COVID- 19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases. In this meta-analysis, we studied the prevalence of cancer among patients with infection and their risks of severe events.

We searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics. We extracted data following PICO (patient, intervention, comparison and outcome) chart. Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data. We assessed the studies' risk of bias in accordance to the adjusted Joanna Briggs Institute. We estimated the prevalence or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects.

Out of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19. The total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), higher than that of the total cancer rate (0.29%) in China. Stratification analysis showed that the overall cancer prevalence of COVID-19 patients in China was 2.59% (95% CI, 1.72% to 3.90%), and the prevalence reached 3.79% in Wuhan (95% CI, 2.51% to 5.70%) and 2.31% (95% CI, 1.16% to 4.57%) in other areas outside Wuhan in China. The incidence of ICU admission in cancer patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%), much higher than the overall rates of COVID-19 patients in China. The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes (OR 1.32; 95% CI, 0.42 to 4.11; p=0.19) , hypertension (OR 1.27; 95% CI, 0.35 to 4.62; p=0. 13) , and respiratory diseases (OR 0.79; 95% CI, 0.47 to 1.33; p=0.45).

The pandemic of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) has caused 4,794,932 confirmed cases and 316,420 deaths globally by May 7, 2020 , affecting almost all the countries in the world. 1 WHO announced COVID-19 as a public health emergency of international concern on January 30, 2020. Most COVID-19 cases experience mild to moderate respiratory symptoms or signs such as fever and cough, and will recover without special treatment.

Unfortunately, the elder people, and those suffering underlying medical conditions such as cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop into more serious conditions, including multiple organ dysfunction syndrome or even death. [2] [3] [4] Cancer is a major public health problem worldwide and is the second leading cause of death in the United States. Recent research had shown that there were about 24.5 million cancer cases worldwide and 9.6 million cancer deaths in 2017. In 2020, the number of new cancer cases and cancer related death is estimated to reach1,806,590 and 606,520 in the US, respectively. 5 Cancer patients are more susceptible to infections than those without cancer due to the systemic immunosuppression caused by the malignancy itself or anticancer treatments, such as chemo-radiation. [6] [7] [8] [9] Therefore, it is conceivable that cancer patients are at higher risk of COVID-19 infection. Moreover, unplanned interruptions of regular anti-tumor therapies, due to the overloaded healthcare systems in the pandemic battle, expose cancer patients' adverse clinical risks of uncontrolled primary disease. Furthermore, some tumor markers such as CEA, CA-125 can be elevated and positively correlated with the pathological progression of COVID-19 infection, which may increase the cancer detection rate. 10 The relationship between cancer and COVID-19 has drawn great attention from the beginning of the pandemic. An early study by Liang et al reported a cancer prevalence of 1.13% (95% CI, 0.61% to 1.65%) among 1,590 cases of COVID-19 in China (only 18 patients with cancer), which was higher compared with the overall cancer incidence of 0.29% in the Chinese population. 11 More importantly, cancer patients with COVID-19 had a higher risk of severe events (a composite end point defined as the percentage of patients who were admitted to the intensive care unit We used random-effects model if the I 2 value was more than 50%. We also performed a multi-group subgroup analysis to explore the source of heterogeneity. 

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 24, 2020. .

Using our searching principles, we retrieved 2,551 studies from three databases between Dec 1st, 2019 and May 3rd, 2020, among which, 32 studies comprising 

We first analyzed the cancer prevalence rates in COVID-19 patients. As shown in Figure 1 , the total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), which is higher than the total cancer rate (0.29%) in China.

When analyzing in subgroups of different sample size, the prevalence showed some variation. The prevalence of cancer was 4.16% (95% CI, 2.80% to 6.14%) in the subgroup whose sample size was ≤ 100, and 3.99% (95% CI, 2.96% to 5.37%) in the subgroup whose sample size was >100 ( Figure 2 ). This observation is consistent and comparable with the analysis by Aakash Desai. 12 We then analyzed the cancer prevalence based on patients' geographic location.

The overall cancer prevalence of COVID-19 patients was 2.59% (95% CI, 1.72% to 3.90%) in China, 3.85% (95% CI, 1.45% to 9.80%) in Japan, and 3.57% (95% CI, 0.50% to 21.42%) in Korea (Figure 1 ). The prevalence was higher in Italy and USA, which reached 11.35% (95% CI, 10.19% to 12.61%) and 6.09% (95% CI, 5.13% to 7.21%), respectively ( Figure 1) . Moreover, the cancer prevalence of COVID-19 patients in Wuhan was 3.79% (95% CI, 2.51% to 5.70%), higher than the average . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 24, 2020. . level of China ( Figure 3 ).

Our analyses clearly showed that the cancer prevalence of COVID-19 patients was higher than that of the general population. In USA and European countries, the prevalence was higher than in China and other Asian countries. In China, the prevalence in Wuhan was higher than in other areas of China (Figure1 and 3) .

In China, the incidence of ICU admission in COVID19 patients with cancer was 38.77% (95% CI, 26.04% to 53.24%) ( Figure 4 ). In Wuhan, the incidence of ICU 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. .

The quality of the included literature was satisfactory. Insufficient number of patients and incomplete coverage of the population were the main cause of low quality literature (eFigure 1), which we excluded. We performed sensitivity analysis of the included studies to assess their stability. After each study was excluded in turn, we found no significant difference in the results of the analysis (eTable 4,5). The funnel plot and Egger test results showed the risk of publication bias is low (p-value = 0.35) (eFigure 5).

The heterogeneity among our study subgroups was high. In the subgroup mortality analysis, the heterogeneity parameter I 2 were >50% in all subgroups except group IA (sample size ≤100). So, the random-effects model was deployed.

A comprehensive analysis of cancer prevalence and severe events among patients with COVID-19 can serve as an important reference for oncology clinicians and healthcare policy makers. A few existing studies focused mainly on the prevalence analysis of cancer patients with COVID-19, lacking a comparison of the prevalence or risk for severe events among different areas. 11, 12 We performed a systematic review on the prevalence of cancer and risks of severe events among patients with COVID-19 using a collection of sparse binomial data from published studies. To our knowledge, this is the largest and most comprehensive meta-analysis of the prevalence and fatality analysis of cancer among patients with COVID-19 to date.

In this study, we found that the total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), which was significantly higher than that of the total cancer rate (0.29%) in China. 47 In other words, approximately 3 in 100 patients with COVID-19 had suffered from superimposed malignancy. The higher prevalence of cancer in COVID19 patients could be due to multiple factors. Firstly, caner is more common among senior patients, who are also susceptible to COVID19.

Secondly, due to primary disease and the anticancer treatment, cancer patients are immune compromised, hence they are more vulnerable to viral infection. Thirdly, COVID19 infection has been shown to elevate the serum level of some cancer biomarkers such as CEA and CA19-9 etc., which may increase the cancer detection rate in this population. 10 The cancer prevalence in COVID19 patients in the city of Wuhan was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . significantly higher than the rest of China. Meanwhile, it was significantly higher in European and American countries than in Asian countries. The geographical differences cannot be explained by factors like race or climate. It seems to be associated with overall incidence of COVID19 infection in those affected areas.

Therefore, effective control of COVID19 infection, especially non-pharmaceutical interventions, could potentially reduce the cancer prevalence. 48 In addition to the high prevalence, we found that nearly a third of cancer patients with COVID-19 experienced aggravated conditions and were admitted to ICU, which was apparently higher than total COVID-19 patients. Moreover, fatality in cancer patients with COVID-19 was about 24.32% (95% CI, 13.95% to 38.91%), also significantly higher than the rate of total patients with COVID-19 (about 3-7%). 49 Factors that affected cancer prevalence mentioned above might also explain the worse prognosis of cancer patients with COVID19. Firstly, individuals with cancer are generally older, 50 which has been shown to express higher levels of angiotensin-converting enzyme II (ACE2), a receptor for SARS-CoV-2 entry into the cell. 51 Secondly, cancer patients often suffer from immunosuppression, like lymphopenia, which often results in the impairment of the required immune response and may lead to viral propagation, tissue destruction, and progression to severe stages of the disease in ACE2-rich tissues . 52 Meanwhile, the overload in the hospitals may prevent timely and sufficient medical care for COVID19 patients with cancer, also leading to high fatality. Severe events are not only a major public health issue, but also a serious economic concern. Although health care personnel and resources were heavily allocated to ICU and treating severe cases, the outcomes were far from satisfactory. Thus, prevention of CoVID19 infection using strict quarantine and social distance measures is essential to protect cancer patients from worsening their health conditions. The outcome of cancer patients with COVID19 was also compared with other morbidities, especially chronic diseases, which were thought as risk factors for severe event in patients with COVID-19. A meta-analysis by Yang CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . superimposed heart disease is the highest cause of death among all complications for COVID-19 patients. 55 severe events, which was followed by lung cancer, and patients with metastatic cancer hade much higher incidence of severe events than those with non-metastatic cancers. Moreover, cancer patients who had received surgery tended to have higher risks of severe events than other treatments except immunotherapy. 56 We anticipate further investigations on these issues in broader geographic and clinical settings.

Our meta-analysis studied the cancer prevalence and risks of severe events in COVID-19 patients by accommodating fully reported and censored data from diverse literature. But this meta-analysis has limitations. Small-study effects were observed when studies with smaller sample sizes had different incidences and wider CIs for fatality in patients with COVID-19 and cancer. Although the forest plots showed no asymmetry favoring cancer fatality studies, this meta-analysis is subject to publication bias given that all of our analyses were based on publications. In addition, this study is subject to any biases or errors of the original investigators, and the results are generalizable only to patient groups with COVID-19. Meanwhile, it currently cannot summarize the prevalence or risk of severe events of different types of cancer in COVID-19 patients due to the lack of enough data.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. .

In summary, using the largest dataset to date, our meta-analysis has clearly demonstrated that (1) there is higher prevalence of COVID19 infection in cancer patients, (2) when COVID19 infection occur in a patient with cancer, the patient is more likely to develop severe clinical events. Patients with chronic health conditions require more stringent preventive measures and more delicate therapeutic strategies during the COVID19 pandemic.

QS, JXH and EC. Z had access to all the data included in the study and are responsible for the completeness of the data and the accuracy of our analysis. JXH, HSL and ZZ helped to design the study. QS, DYW, and BWC contributed to the statistical analysis and the revision of this manuscript. ZHG and CGZ approved the final manuscript.

All other authors declare no competing interests. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020.

. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020.

. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 24, 2020. . 

We have enclosed a manuscript titled "Prevalence and risks of severe events for cancer patients with COVID-19 infection: a systematic review and meta-analysis" by Su et al. In this study, a meta-analysis was carried out to evaluate the prevalence of cancer patients in COVID19 infection and their risks of severe events. We searched related studies from diverse literatures, extracted data following PICO chart, and carried out statistical analyses using R Studio (version 3.5.1) on the group-level data. We estimated the overall prevalence and risks for severe events including admission into intensive care unit or death in cancer patients with COVID19 worldwide and also made preliminary comparisons among different countries and territories. Meanwhile, comparisons between cancer and other comorbidities including diabetes, hypertension, cardiovascular and respiratory diseases were also made concerning the prevalence, risks for ICU admission and death during COVID19 infection.

The major findings from this study can be described as, 1) The total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%) worldwide, while in China was 2.59% (95% CI, 1.72% to 3.90%), 3.79% in Wuhan (95% CI, 2.51% to 5.70%).

2) The prevalence of cancer in COVID19 was higher in USA and European countries than in Asian countries.

3) The incidence of ICU admission in cancer patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%).

4) The fatality in COVID patients with cancer was lower than those with cardiovascular disease, but comparable with other comorbidities such as diabetes, hypertension, and respiratory diseases.

The listed authors have participated and have made significant contribution to the study, and will take the responsibility for the appropriateness regarding the experimental design, acquired methodology, the collection, analysis and summary of the data. As the corresponding author, I have reviewed the final version of the manuscript and approve it for submission.

We also certify that this manuscript has not been published in whole or as part for publication elsewhere. I have read and abided by the statement of ethical standards for manuscripts submitted to your journal. The attached are the required submission items. We believe that the results from this manuscript fit the field readers' interests and warrant for a publication in "medRxiv" as a full length article. Please consider our manuscript seriously and feedback us with valuable scientific critiques. Thank you very much.

We searched Pubmed, Embase and MedRxiv databases for cohort studies and clinical trials of evaluating prevalence of cancer patients with COVID-19 as well as risks of severe clinical events including ICU admission and death in those patients between Dec 1st, 2019 and May 3rd, 2020. Meanwhile, preliminary comparisons concerning cancer prevalence and risks for severe events among different countries were made. Furthermore, risks for ICU admission and death were also made between cancer patients with patients suffering other comorbidities including diabetes, hypertension, cardiovascular and respiratory diseases.

Conclusions of previous similar meta-analyses were limited due to small sample sizes, which also did not make comparisons among different countries or territories. Meanwhile, the relative risks of severe events for cancer over other underlying diseases for COVID19 patients were largely unknown. Our search did not retrieve any systematic review of information on prevalence and risks of severe events of cancer patients in COVID19 infection.

We did a systematic review of 32 studies comprising 21,248 cases with confirmed COVID-19. To our knowledge, this is the largest and most comprehensive meta-analysis to date on the prevalence of cancer . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 24, 2020. . patients with COVID19 infection and their risks of ICU admission or death. According to our analyses, the total prevalence of cancer in COVID-19 patients was 3.97% worldwide. In China, the overall cancer prevalence of COVID-19 patients was 2.59%, and in Wuhan, the city where COVID-19 was first reported, the prevalence reached 3.79% while 2.31%in other areas outside Wuhan in China. The prevalence was higher in Italy and USA, reaching 11.35% and 6.09%, respectively. The incidence of ICU admission in cancer patients with COVID-19 was 26.80% worldwide, and the mortality was 24.32% (95% CI, 13.95% to 38.91%) according to the data available from Wuhan and European countries. The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes, hypertension, and respiratory diseases. The ICU admission rate was close with each other in cancer patients and patients with other comorbidities mentioned above in COVID19 infection.

Our findings based on larger population provide some clarification in multiple aspects and have implications for cancer patients, oncology clinicians as well as policy makers all around the world, especially in COVID19 outbreak countries. The prevalence of cancer in COVID19 is higher than cancer rates in total population. Special attention should paid . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 24, 2020. . on cancer patients during the pandemic, and more strict quarantine measures, longer social distances are applicable to cancer patients, and more appropriate personal protective equipment (eg, face masks) should be provided for them, especially in circumstances of high risks. Besides high prevalence, high rates of ICU admission and death were also observed in cancer patients with COVID19, possibly resulting from infection itself or a delay of timely medication for cancer. Thus, the balance between protection from COVID19 infection and cancer progression due to inadequate or delayed medication should be well handled for oncologists and health policy makers. The ICU admission rate of cancer patients is similar to common chronic diseases like diabetes, hypertension, cardiovascular and respiratory diseases. However, the mortality of cardiovascular disease patients with COVID19 is higher than patients with cancer, diabetes, hypertension and respiratory disease. Thus, the policies of medical resource allocation were supposed to include cancer as one priority, at least equal to other common chronic diseases.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 24, 2020. .

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Covid-19: risk factors for severe disease and death

Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China

Cancer statistics

Nosocomial infections in patients with cancer

Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer

Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 Pathways

Myeloid suppressor cells in cancer and autoimmunity

Elevations of serum cancer biomarkers correlate with severity of COVID-19

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia

Risk Factors Associated With Acute Respiratory Distress Syndrome